| Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine C Keech, G Albert, I Cho, A Robertson, P Reed, S Neal, JS Plested, M Zhu, ... New england journal of medicine 383 (24), 2320-2332, 2020 | 1270 | 2020 |
| Kyratsous CA J Hansen, A Baum, KE Pascal, V Russo, S Giordano, E Wloga, BO Fulton, ... Studies in humanized mice and convalescent humans yield a SARS-CoV-2 …, 2020 | 1051 | 2020 |
| Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail J Hansen, A Baum, KE Pascal, V Russo, S Giordano, E Wloga, BO Fulton, ... Science 369 (6506), 1010-1014, 2020 | 977 | 2020 |
| Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms DE Gordon, J Hiatt, M Bouhaddou, VV Rezelj, S Ulferts, H Braberg, ... Science 370 (6521), eabe9403, 2020 | 614 | 2020 |
| Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2 S Saadat, ZR Tehrani, J Logue, M Newman, MB Frieman, AD Harris, ... Jama 325 (14), 1467-1469, 2021 | 426 | 2021 |
| SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice JH Tian, N Patel, R Haupt, H Zhou, S Weston, H Hammond, J Logue, ... Nature communications 12 (1), 372, 2021 | 394 | 2021 |
| A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics L Si, H Bai, M Rodas, W Cao, CY Oh, A Jiang, R Moller, D Hoagland, ... Nature biomedical engineering 5 (8), 815-829, 2021 | 254 | 2021 |
| Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail J Dong, SJ Zost, AJ Greaney, TN Starr, AS Dingens, EC Chen, RE Chen, ... Nature microbiology 6 (10), 1233-1244, 2021 | 247 | 2021 |
| Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia SB Kennedy, F Bolay, M Kieh, G Grandits, M Badio, R Ballou, R Eckes, ... New England Journal of Medicine 377 (15), 1438-1447, 2017 | 241 | 2017 |
| Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo S Weston, CM Coleman, R Haupt, J Logue, K Matthews, Y Li, HM Reyes, ... Journal of virology 94 (21), 10.1128/jvi. 01218-20, 2020 | 227 | 2020 |
| Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 B Boras, RM Jones, BJ Anson, D Arenson, L Aschenbrenner, ... Nature communications 12 (1), 6055, 2021 | 201 | 2021 |
| Defining the risk of SARS-CoV-2 variants on immune protection MM DeGrace, E Ghedin, MB Frieman, F Krammer, A Grifoni, A Alisoltani, ... Nature 605 (7911), 640-652, 2022 | 134 | 2022 |
| Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail J Dong, SJ Zost, AJ Greaney, TN Starr, AS Dingens, EC Chen, RE Chen, ... BioRxiv, 2021.01. 27.428529, 2021 | 127 | 2021 |
| Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19 B Boras, RM Jones, BJ Anson, D Arenson, L Aschenbrenner, ... BioRxiv, 2020.09. 12.293498, 2020 | 111 | 2020 |
| Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination MJ Gorman, N Patel, M Guebre-Xabier, AL Zhu, C Atyeo, KM Pullen, ... Cell Reports Medicine 2 (9), 2021 | 97 | 2021 |
| Single-cell profiling of Ebola virus disease in vivo reveals viral and host dynamics D Kotliar, AE Lin, J Logue, TK Hughes, NM Khoury, SS Raju, ... Cell 183 (5), 1383-1401. e19, 2020 | 79 | 2020 |
| SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice JH Tian, N Patel, R Haupt, H Zhou, S Weston, H Hammond, J Lague, ... BioRxiv, 2020.06. 29.178509, 2020 | 79 | 2020 |
| Ebola virus neutralizing antibodies detectable in survivors of theYambuku, Zaire outbreak 40 years after infection AW Rimoin, K Lu, MS Bramble, I Steffen, RH Doshi, NA Hoff, P Mukadi, ... The Journal of infectious diseases 217 (2), 223-231, 2018 | 72 | 2018 |
| Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms AC Puhl, EJ Fritch, TR Lane, LV Tse, BL Yount, CQ Sacramento, ... ACS omega 6 (11), 7454-7468, 2021 | 71 | 2021 |
| Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics L Si, H Bai, M Rodas, W Cao, CY Oh, A Jiang, A Nurani, DY Zhu, G Goyal, ... BioRxiv 13, 2020, 2020 | 71 | 2020 |
